SLC5A2 and heart failure: In the comparative analysis by Vaduganathan et al. [11], comprehensive disease-modifying therapy including both SGLT2 inhibitors and ARNIs, alongside beta-blockers and MRAs, resulted in a remarkable 62% relative risk reduction in cardiovascular death or first heart failure hospitalization, with up to 8.3 additional years of event-free survival in younger patients.